<span item_type="fundamental" item_id="0e3356ebf3d212c2cf55d2cfaf73ea8d" counter_id="ST/US/ANIK" env="prod"></span><span item_type="announcement" item_id="579403122809443201" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 27.82 M, beating the estimate of USD 27.8 M.</p><p>EPS: As of FY2025 Q3, the actual value is USD -0.22, beating the estimate of USD -0.27.</p><p></p><h3>Financial Results Summary</h3><p>Anika Therapeutics, Inc. announced its financial results for the third quarter ended September 30, 2025. The company did not provide specific financial metrics such as segment revenue, net income, gross margin, operating profit, operating margin, operating costs, operating cash flow, or free cash flow in the provided reference. Therefore, no detailed financial data can be extracted from the current document.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/898437/000117184325007003/f8k_110525.htm"></span></p><h3>Revenue</h3><ul><li>Total revenue for the third quarter of 2025 was $27.8 million, a decrease of 6% compared to the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/898437/000117184325007003/exh_991.htm"></span></li><li>OEM Channel revenue was $15.8 million, a decrease of 20% year over year.<span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/898437/000117184325007003/exh_991.htm"></span></li><li>Commercial Channel revenue was $12.0 million, an increase of 22% year over year.<span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/898437/000117184325007003/exh_991.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>Gross margin for the third quarter was 56%.<span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/898437/000117184325007003/exh_991.htm"></span></li><li>Operating expenses were $18.8 million, a decrease of 3% compared to the third quarter of 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/898437/000117184325007003/exh_991.htm"></span></li><li>Loss from continuing operations was - $3.2 million, or - $0.22 per share.<span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/898437/000117184325007003/exh_991.htm"></span></li><li>Adjusted net income from continuing operations was $0.7 million, or $0.04 per share.<span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/898437/000117184325007003/exh_991.htm"></span></li><li>Adjusted EBITDA was $0.9 million.<span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/898437/000117184325007003/exh_991.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Cash provided by operating activities for the total company was $6.9 million.<span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/898437/000117184325007003/exh_991.htm"></span></li><li>Cash balance at the end of the quarter was $58.0 million.<span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/898437/000117184325007003/exh_991.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>The Integrity Implant System and Hyalofast® showed strong growth, with Integrity procedures growing for the sixth consecutive quarter.<span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/898437/000117184325007003/exh_991.htm"></span></li><li>Cingal® achieved a commercial milestone of more than one million injections worldwide since 2016.<span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/898437/000117184325007003/exh_991.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>Anika reaffirms its fiscal 2025 guidance, maintaining revenue ranges for the Commercial Channel at $47 to $49.5 million, up 12% to 18% year over year, and for the OEM Channel at $62 to $65 million, down 16% to 20% year over year.<span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/898437/000117184325007003/exh_991.htm"></span></li><li>The company maintains Adjusted EBITDA as a percent of revenue of positive 3% to negative 3%.<span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/898437/000117184325007003/exh_991.htm"></span></li><li>Anika is commencing a $15 million 10b5-1 share repurchase, expected to be completed by June 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/898437/000117184325007003/exh_991.htm"></span></li></ul>

Anika Therap | 8-K: FY2025 Q3 Revenue Beats Estimate at USD 27.82 M